FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174202425> ?p ?o ?g. }

• W3174202425 abstract "Triple negative breast cancer (TNBC) is a heterogeneous group of clinically aggressive diseases. TNBC patients have high risk of recurrence and metastasis, and current treatment options remain limited. Cancer stem-like cells (CSCs) have been linked to cancer initiation, progression and chemotherapy resistance. Therefore, CSC-targeted therapies are keenly sought. There is strong evidence for the involvement of canonical-Notch signaling in TNBC, however the role of non-canonical Notch signaling in TNBC remains unknown. Notch1 is highly expressed in Basal-like 1 (BL1) and especially Mesenchymal (M) TNBCs. Expression of Notch1 and its ligand Jagged1 correlate with poor prognosis. Moreover, strong evidence supports key roles of different Notch paralogs in breast CSCs. Here, we demonstrate that Notch activation by Jagged1-expressing stromal cells enhances transcription of the anti-apoptotic gene cIAP-2 (BIRC3), a known NF-κB target. This event is dependent on recruitment to the cIAP-2 promoter of NF-κB subunits, IKKα and Notch1. Short term exposure of MDA-MB-231 cells (M, PTEN wild-type), but not MDA-MB-468 cells (BL1, PTEN-null) to recombinant Jagged1 leads to AKT phosphorylation. This is suppressed by AKT inhibitors, IKK inhibitors, and dual mTORC1/2 inhibitors but not an mTORC1-selective inhibitor. These observations support a model where canonical and non-canonical mechanisms downstream of Notch1 trigger AKT phosphorylation and NF-κB activation in PTEN wild type TNBC cells. Importantly, we find co-localization of Notch1 with Mitochondria in MDA-MB-231 cells by confocal microscopy and Western blot of isolated mitochondrial fractions. We demonstrate that recombinant Jagged1 increases the metabolism of TNBC cells. Knockdown of Notch1 or IKKα by siRNA decreases mitochondrial respiration and glycolysis. CSCs derived from MDA-MB-231 cells have increased Notch1, p-AKT, and oxidative metabolism compared to non-stem cells. AKT inhibition or IKK inhibition decreases both mitochondrial respiration and glycolysis of TNBC derived CSCs. Pharmacological inhibition of Notch cleavage by gamma secretase inhibitor (PF-03084014) in combination with AKT inhibitor (MK-2206) or IKK inhibitor (Bay11-7082) blocks CD90hi or CD44+CD24low sorted secondary mammospheres formation. Notably, we find similar results in TNBC patient derived xenograft (PDX) models. However, Notch inhibition may have adverse effects on tumor immunity, due to the role of Notch in CD4 and CD8 T-cell activation. Thus, we explored an immunocompetent tumor mouse model to study the effects of these pharmacological interventions in that setting. We developed an immunocompetent TNBC mouse model by injecting TNBC mouse cells (C0321) into mammary fat pads of isogenic FVB female mice. Combination treatments with GSI (PF-03084014) and AKT inhibitor (MK-2206) significantly delayed tumor growth as well as decreased CSCs number in that model. These data suggest that combination treatments affecting the intersection of Notch and AKT pathways have potential therapeutic applications in targeting CSCs in TNBC cases with high Notch1 expression. The possible immunological effects of such combination treatments require additional investigation. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal." @default.
• W3174202425 created "2021-07-05" @default.
• W3174202425 creator A5041222618 @default.
• W3174202425 creator A5041301571 @default.
• W3174202425 creator A5048983251 @default.
• W3174202425 creator A5051275013 @default.
• W3174202425 creator A5056296095 @default.
• W3174202425 creator A5057095327 @default.
• W3174202425 creator A5058688886 @default.
• W3174202425 creator A5071108571 @default.
• W3174202425 creator A5075876145 @default.
• W3174202425 creator A5080769954 @default.
• W3174202425 creator A5087313882 @default.
• W3174202425 date "2018-04-01" @default.
• W3174202425 modified "2023-10-14" @default.
• W3174202425 title "Characterization and Targeting Cancer Stem‐like Cells in Triple Negative Breast Cancer" @default.
• W3174202425 doi "https://doi.org/10.1096/fasebj.2018.32.1_supplement.835.11" @default.
• W3174202425 hasPublicationYear "2018" @default.
• W3174202425 type Work @default.
• W3174202425 sameAs 3174202425 @default.
• W3174202425 citedByCount "0" @default.
• W3174202425 crossrefType "journal-article" @default.
• W3174202425 hasAuthorship W3174202425A5041222618 @default.
• W3174202425 hasAuthorship W3174202425A5041301571 @default.
• W3174202425 hasAuthorship W3174202425A5048983251 @default.
• W3174202425 hasAuthorship W3174202425A5051275013 @default.
• W3174202425 hasAuthorship W3174202425A5056296095 @default.
• W3174202425 hasAuthorship W3174202425A5057095327 @default.
• W3174202425 hasAuthorship W3174202425A5058688886 @default.
• W3174202425 hasAuthorship W3174202425A5071108571 @default.
• W3174202425 hasAuthorship W3174202425A5075876145 @default.
• W3174202425 hasAuthorship W3174202425A5080769954 @default.
• W3174202425 hasAuthorship W3174202425A5087313882 @default.
• W3174202425 hasConcept C11960822 @default.
• W3174202425 hasConcept C121608353 @default.
• W3174202425 hasConcept C161879069 @default.
• W3174202425 hasConcept C185592680 @default.
• W3174202425 hasConcept C2777609662 @default.
• W3174202425 hasConcept C2779013556 @default.
• W3174202425 hasConcept C2780110267 @default.
• W3174202425 hasConcept C28328180 @default.
• W3174202425 hasConcept C502942594 @default.
• W3174202425 hasConcept C530470458 @default.
• W3174202425 hasConcept C54355233 @default.
• W3174202425 hasConcept C55427017 @default.
• W3174202425 hasConcept C62478195 @default.
• W3174202425 hasConcept C75217442 @default.
• W3174202425 hasConcept C86554907 @default.
• W3174202425 hasConcept C86803240 @default.
• W3174202425 hasConcept C95444343 @default.
• W3174202425 hasConcept C98490376 @default.
• W3174202425 hasConceptScore W3174202425C11960822 @default.
• W3174202425 hasConceptScore W3174202425C121608353 @default.
• W3174202425 hasConceptScore W3174202425C161879069 @default.
• W3174202425 hasConceptScore W3174202425C185592680 @default.
• W3174202425 hasConceptScore W3174202425C2777609662 @default.
• W3174202425 hasConceptScore W3174202425C2779013556 @default.
• W3174202425 hasConceptScore W3174202425C2780110267 @default.
• W3174202425 hasConceptScore W3174202425C28328180 @default.
• W3174202425 hasConceptScore W3174202425C502942594 @default.
• W3174202425 hasConceptScore W3174202425C530470458 @default.
• W3174202425 hasConceptScore W3174202425C54355233 @default.
• W3174202425 hasConceptScore W3174202425C55427017 @default.
• W3174202425 hasConceptScore W3174202425C62478195 @default.
• W3174202425 hasConceptScore W3174202425C75217442 @default.
• W3174202425 hasConceptScore W3174202425C86554907 @default.
• W3174202425 hasConceptScore W3174202425C86803240 @default.
• W3174202425 hasConceptScore W3174202425C95444343 @default.
• W3174202425 hasConceptScore W3174202425C98490376 @default.
• W3174202425 hasIssue "S1" @default.
• W3174202425 hasLocation W31742024251 @default.
• W3174202425 hasOpenAccess W3174202425 @default.
• W3174202425 hasPrimaryLocation W31742024251 @default.
• W3174202425 hasRelatedWork W1524403850 @default.
• W3174202425 hasRelatedWork W1607074945 @default.
• W3174202425 hasRelatedWork W1992367938 @default.
• W3174202425 hasRelatedWork W2180010206 @default.
• W3174202425 hasRelatedWork W2740940305 @default.
• W3174202425 hasRelatedWork W2793378316 @default.
• W3174202425 hasRelatedWork W2886756658 @default.
• W3174202425 hasRelatedWork W2912656088 @default.
• W3174202425 hasRelatedWork W4246624669 @default.
• W3174202425 hasRelatedWork W4361959649 @default.
• W3174202425 hasVolume "32" @default.
• W3174202425 isParatext "false" @default.
• W3174202425 isRetracted "false" @default.
• W3174202425 magId "3174202425" @default.
• W3174202425 workType "article" @default.